Share repurchase for employee incentive programs
Idag, 09:00
Gubra today announces that it has instructed AL Sydbank A/S to buy back up to 32,000 Gubra shares to hedge the company's obligations arising from certain of the company's employee share incentive programs (Restricted Stock Units granted in 2026 and the newly launched Employee Share Purchase Plan).
The amount of shares corresponds to 0.2% of the total share capital in Gubra.
Contacts at Gubra
Media: Marianne Thomas (mho@gubra.dk, +45 2483 2663)
Investors: Kristian Borbos (kbo@gubra.dk, +45 3080 8035) and Adam Lange (adl@gubra.dk, +45 6646 1589)
About Gubra
Gubra, founded in 2008 in Denmark and listed on NASDAQ Copenhagen, is a disease-agnostic techbio company specialized in peptide-based drug discovery and preclinical contract research services. Gubra’s activities are focused on the early stages of drug development and are organized in three main business units – Biotech, CRO, and Ventures. The business areas create a unique entity capable of generating a steady cash flow from the CRO business while investing in high-impact biotech R&D projects with significant value inflection potential through partnerships. Gubra has around 300 employees and had revenue of DKK 2.6 billion (around $400 million) in 2025. See www.gubra.dk for more information.
Ämnen i artikeln
Share repurchase for employee incentive programs
Idag, 09:00
Gubra today announces that it has instructed AL Sydbank A/S to buy back up to 32,000 Gubra shares to hedge the company's obligations arising from certain of the company's employee share incentive programs (Restricted Stock Units granted in 2026 and the newly launched Employee Share Purchase Plan).
The amount of shares corresponds to 0.2% of the total share capital in Gubra.
Contacts at Gubra
Media: Marianne Thomas (mho@gubra.dk, +45 2483 2663)
Investors: Kristian Borbos (kbo@gubra.dk, +45 3080 8035) and Adam Lange (adl@gubra.dk, +45 6646 1589)
About Gubra
Gubra, founded in 2008 in Denmark and listed on NASDAQ Copenhagen, is a disease-agnostic techbio company specialized in peptide-based drug discovery and preclinical contract research services. Gubra’s activities are focused on the early stages of drug development and are organized in three main business units – Biotech, CRO, and Ventures. The business areas create a unique entity capable of generating a steady cash flow from the CRO business while investing in high-impact biotech R&D projects with significant value inflection potential through partnerships. Gubra has around 300 employees and had revenue of DKK 2.6 billion (around $400 million) in 2025. See www.gubra.dk for more information.
Ämnen i artikeln
Rapportperioden
Aktieanalys
Rapportperioden
Aktieanalys
Marknadsöversikt
1 DAG %
Senast
1 mån
